# CYTK catalysts: CYTOKINETICS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cytk/catalysts

> CYTOKINETICS INC (CYTK) has 8 upcoming catalysts. The next is the MYQORZO® (aficamten) topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for CYTK?

CYTOKINETICS INC (CYTK) has 8 upcoming catalysts. The next is the MYQORZO® (aficamten) topline data readout, early 2027. Press release filed with the SEC (EX-99): "We expect to present topline data in early 2027." [Calendar and source filings](https://sec-api.dev/companies/cytk/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-447198, https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/cytk/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | CYTOKINETICS INC |
| Ticker | CYTK (Nasdaq) |
| SEC CIK | 1061983 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/cytk |

## Cash runway

Cash $1.58B as of 2026-09-30; quarterly burn $124.0M; about 38.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-447408).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 28, 2023 | [Omecamtiv complete response letter (CRL)](https://sec-api.dev/pdufa/omecamtiv) | CYTK | chronic heart failure with HFrEF | completed, complete response letter | "For example, the CRL we received on February 28, 2023 in connection to our NDA for omecamtiv mecarbil stated the results of GALACTIC-HF were not sufficiently persuasive to establish substantial evidence of effectiveness for reducing the risk of heart failure events and cardiovascular death in adults with chronic heart failure with HFrEF, and on March 31, 2023, we announced the discontinuation of COURAGE-ALS, our Phase 3 clinical trial of reldesemtiv in patients with ALS, due to futility." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm)) |
| Dec 2023 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK |  | completed, positive | "In December 2023, we announced positive topline results from SEQUOIA-HCM, the Phase 3 trial for aficamten." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm)) |
| Nov 2024 | [MYQORZO® (aficamten) NDA/BLA acceptance](https://sec-api.dev/pdufa/aficamten) | CYTK |  | completed | "In November 2024, we announced that FDA accepted our NDA for aficamten." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm)) |
| February 27, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/cytk-ex99_1.htm)) |
| May 2025 | [CYTOKINETICS INC topline data readout](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed, positive | "In May 2025, the company announced positive topline results from MAPLE-HCM and in August 2025 the company presented the primary results of MAPLE-HCM at the European Society of Cardiology Congress 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm)) |
| May 2025 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK |  | scheduled | "We expect to share topline results in May 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm)) |
| May 6, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm)) |
| August 7, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/cytk-ex99_1.htm)) |
| September 26, 2025 | [MYQORZO® (aficamten) NDA/BLA acceptance](https://sec-api.dev/pdufa/aficamten) | CYTK |  | completed | "For example, the FDA recently accepted and filed our NDA for aficamten for the treatment of oHCM and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025, which was subsequently extended to December 26, 2025 as a result of FDA considering our submission of a proposed REMS to be a major amendment to the NDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm)) |
| September 26, 2025 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | oHCM | delayed | "We have submitted an NDA to FDA for aficamten for the treatment of oHCM, which was accepted for filing with a PDUFA target action date of September 26, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm)) |
| November 5, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm)) |
| December 19, 2025 | [MYQORZO® (aficamten) FDA approval](https://sec-api.dev/pdufa/aficamten) | CYTK | To treat symptomatic obstructive hypertrophic cardiomyopathy | completed, approved | "Myqorzo \| aficamten \| 12/19/2025 \| To treat symptomatic obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| December 26, 2025 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | with obstructive hypertrophic cardiomyopathy | completed, approved | "Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm)) |
| Jan 2026 | [MYQORZO® (aficamten) NDA/BLA acceptance](https://sec-api.dev/pdufa/aficamten) | CYTK | obstructive HCM | completed | "Finally, in January 2026 we submitted, and the FDA subsequently accepted for filing, a supplemental NDA for MYQORZO to the FDA requesting to include the results of MAPLE-HCM, a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM, in the label." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm)) |
| February 24, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-ex99_1.htm)) |
| Q2 2026 | [CYTOKINETICS INC topline data readout](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | scheduled | "Expect to Share Topline Results from ACACIA-HCM in Q2 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-ex99_1.htm)) |
| May 5, 2026 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK |  | completed, positive | "On May 5, 2026, we announced positive topline results from ACACIA-HCM." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm)) |
| May 5, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm)) |
| August 6, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-ex99_1.htm)) |
| August 31, 2026 | [MYQORZO® (aficamten) primary completion](https://sec-api.dev/pdufa/aficamten) | CYTK | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | completed | "NCT06081894 (A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-31 (ACTUAL); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06081894)) |
| Aug to Nov 2026 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | scheduled | "NCT06081894 (A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-31 (ACTUAL); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06081894)) |
| September 2026 | [Ck-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) primary completion](https://sec-api.dev/pdufa/ck-4021586) | CYTK | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | delayed | "NCT06793371 (AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06793371)) |
| Sep to Dec 2026 | [Ck-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) topline data readout](https://sec-api.dev/pdufa/ck-4021586) | CYTK | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | scheduled | "NCT06793371 (AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06793371)) |
| Q4 2026 | [MYQORZO® (aficamten) NDA/BLA submission](https://sec-api.dev/pdufa/aficamten) | CYTK | non-obstructive HCM | scheduled | "Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm)) |
| November 4, 2026 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm)) |
| November 14, 2026 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | Symptomatic Obstructive HCM | scheduled | "MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM; Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm)) |
| early 2027 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK |  | scheduled | "We expect to present topline data in early 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm)) |
| early 2027 | [CK-4015089 topline data readout](https://sec-api.dev/pdufa/ck-089) | CYTK |  | scheduled | "our expectations to present topline data from the adolescent cohort of CEDAR-HCM in early 2027, to complete patient enrollment in Cohort 1 of AMBER-HFpEF in the fourth quarter of 2026 and to complete patient enrollment in COMET-HF in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm)) |
| September 2027 | [Omecamtiv mecarbil (om) primary completion](https://sec-api.dev/pdufa/omecamtiv-mecarbil-om) | CYTK | Heart Failure; Heart Failure With Reduced Ejection Fraction | scheduled | "NCT06736574 (Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06736574)) |
| Sep to Dec 2027 | [Omecamtiv mecarbil (om) topline data readout](https://sec-api.dev/pdufa/omecamtiv-mecarbil-om) | CYTK | Heart Failure; Heart Failure With Reduced Ejection Fraction | scheduled | "NCT06736574 (Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06736574)) |
| March 2029 | [Aficamten (5 - 20 mg) primary completion](https://sec-api.dev/pdufa/aficamten-5) | CYTK | Symptomatic Hypertrophic Cardiomyopathy (HCM) | scheduled | "NCT04848506 (Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04848506)) |
| Mar to Jun 2029 | [Aficamten (5 - 20 mg) topline data readout](https://sec-api.dev/pdufa/aficamten-5) | CYTK | Symptomatic Hypertrophic Cardiomyopathy (HCM) | scheduled | "NCT04848506 (Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2, PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04848506)) |
| January 2030 | [MYQORZO® (aficamten) primary completion](https://sec-api.dev/pdufa/aficamten) | CYTK | Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy | scheduled | "NCT06412666 (A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06412666)) |
| Jan to Apr 2030 | [MYQORZO® (aficamten) topline data readout](https://sec-api.dev/pdufa/aficamten) | CYTK | Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy | scheduled | "NCT06412666 (A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Cytokinetics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06412666)) |

## Drugs

- [MYQORZO® (aficamten)](https://sec-api.dev/pdufa/aficamten): ohcm, obstructive hcm, symptomatic ohcm, non-obstructive hcm, with obstructive hypertrophic cardiomyopathy, To treat symptomatic obstructive hypertrophic cardiomyopathy, Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
- [Aficamten (5 - 20 mg)](https://sec-api.dev/pdufa/aficamten-5): Symptomatic Hypertrophic Cardiomyopathy (HCM)
- [CK-4015089](https://sec-api.dev/pdufa/ck-089): 
- [Ck-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)](https://sec-api.dev/pdufa/ck-4021586): Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
- [Omecamtiv](https://sec-api.dev/pdufa/omecamtiv): chronic heart failure with hfref, chronic heart failure with hfref, and in march 2023, we
- [Omecamtiv mecarbil (om)](https://sec-api.dev/pdufa/omecamtiv-mecarbil-om): Heart Failure

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cytk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CYTK catalysts: CYTOKINETICS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cytk/catalysts

```bibtex
@misc{secapidev_companies_cytk_catalysts_20261116,
  title        = {CYTK catalysts: CYTOKINETICS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cytk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cytk_catalysts_20261116","title":"CYTK catalysts: CYTOKINETICS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cytk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
